Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMerck KGaA ADR

Merck KGaA ADR

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
34.06 USD 0.85 ( 2.56%)
Last update at 2026-11-04T20:59:00Z
VOLUME
5341
Market Cap
67455.81M
P/E
21.25

Momentum Score

…

Merck KGaA operates as a science and technology company in Germany. The company's Life Science segment offers a range of products, including reagents, consumable, devices, instruments, software, and services for scientific discovery, as well as provides lab water instruments, consumables and services, microbiology and biomonitoring, products, test assays, analytical reagents, and flow cytometry kits and instruments for pharma and biotech, industrial and testing, academics and government, and diagnostic sectors. Its Healthcare segment designs and develops medicines and intelligent devices for treatment of various therapeutics, such as oncology, neurology and immunology, endocrinology, and general medicines. The company's Electronic segment provides semiconductor solutions, such as semiconductor materials, delivery systems and services, and intermolecular services for semiconductor and polymer removal chemistries applications; and display solutions comprising liquid crystals, OLED and quantum materials, reactive mesogens, photoresist materials, smart antenna, and dynamic liquid crystal glazing products, as well as offers liviFlex, a flexible platform, which offers a range of display materials. This segment also provides surface solution, such as cosmetics, effect pigments, and functional solutions; architecture solutions, including switchable windows; and automotive solutions. In addition, it has strategic alliances with Pfizer Inc. and GlaxoSmihKline plc to develop and commercialize active ingredients in immune-oncology; in-licensing agreement with Debiopharm International SA for developing drug candidates for the treatment of head and neck cancer; and out-licensing agreement with MoonLake Immunotherapeutics AG for developing a drug candidate for the treatment of inflammatory diseases. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
33.57
Low
34.10
High
52 Week Price Range
28.59
Low
42.68
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Merck KGaA (ADR MKKGY) is a German science and technology company with businesses in healthcare, life‑science tools and performance materials serving academic, industrial and clinical customers. Long-term growth may be supported by its life‑science franchise, an R&D-driven pharmaceuticals pipeline and demand for specialty chemicals in electronics and semiconductors. Its diversified portfolio and global scale appears positioned to generate steady cash flow and operational synergies.
Major risks include clinical and regulatory setbacks for drug candidates, patent expirations and competitive pressure, exposure to currency and cyclical electronics demand, and limited liquidity for the OTC ADR.

Risk Score
Low

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
33.21
Dividend Yield
1.56%
Revenue TTM
21428.00M
Revenue Per Share
9.87
Gross Profit TTM
13737.00M
Debt / Equity
0.40
ROE
10.26%
Net Debt
9000.00M
ROCE
11.47%
Diluted EPS TTM
1.46

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 4287.00M 3924.00M 2630.00M 1735.00M 1461.00M
Minority interest -14.00M -10.00M 71.00M 73.00M 33.00M
Net income 3326.00M 3055.00M 1987.00M 1320.00M 3374.00M
Selling general administrative 1306.00M 1241.00M 1188.00M 1154.00M 993.00M
Selling and marketing expenses 4097.00M 3714.00M 3572.00M 3653.00M 3408.00M
Gross profit 13705.00M 12336.00M 10699.00M 10146.00M 9454.00M
Reconciled depreciation 2030.00M 1762.00M 1938.00M 1944.00M 1812.00M
Ebit 4474.00M 4179.00M 2985.00M 2120.00M 1897.00M
Ebitda 6744.00M 5962.00M 4729.00M 4228.00M 3709.00M
Depreciation and amortization 2270.00M 1783.00M 1744.00M 2108.00M 1812.00M
Non operating income net other - - - 0.00M 0.00M
Operating income 4474.00M 4179.00M 2985.00M 2120.00M 1727.00M
Other operating expenses 17480.00M 15491.00M 14724.00M 13848.00M 12965.00M
Interest expense 235.00M 272.00M 387.00M 476.00M 339.00M
Tax provision 948.00M 859.00M 637.00M 440.00M 368.00M
Interest income 71.00M 46.00M 39.00M 71.00M 60.00M
Net interest income -164.00M -226.00M -348.00M -406.00M -280.00M
Extraordinary items - - - 0.00M 0.00M
Non recurring - - - 0.00M 0.00M
Other items - - - 0.00M 0.00M
Income tax expense 948.00M 859.00M 637.00M 440.00M 368.00M
Total revenue 22232.00M 19687.00M 17534.00M 16152.00M 14836.00M
Total operating expenses 8953.00M 8140.00M 7889.00M 7842.00M 7583.00M
Cost of revenue 8527.00M 7351.00M 6835.00M 6006.00M 5382.00M
Total other income expense net -187.00M -255.00M -355.00M -385.00M -266.00M
Discontinued operations - - - 28.00M 2303.00M
Net income from continuing ops 3339.00M 3065.00M 1994.00M 1296.00M 1093.00M
Net income applicable to common shares 3326.00M 3055.00M 1987.00M 1320.00M 3374.00M
Preferred stock and other adjustments - - - 0.00M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 48526.00M 45362.00M 41796.00M 43811.00M 36888.00M
Intangible assets 7300.00M 7612.00M 7653.00M 9175.00M 7238.00M
Other current assets 151.00M 94.00M 76.00M 97.00M 99.00M
Total liab 22521.00M 23946.00M 24779.00M 25898.00M 19655.00M
Total stockholder equity 25927.00M 21338.00M 16946.00M 17865.00M 17200.00M
Deferred long term liab - - - 0.00M 0.00M
Other current liab 6720.00M 839.00M 666.00M 564.00M 3828.00M
Common stock 565.00M 565.00M 565.00M 565.00M 565.00M
Capital stock 565.00M 565.00M 565.00M 565.00M 565.00M
Retained earnings 18463.00M 15134.00M 12378.00M 11507.00M 12525.00M
Other liab 3808.00M 5244.00M 5763.00M 5408.00M 4457.00M
Good will 18415.00M 17004.00M 15959.00M 17141.00M 13764.00M
Other assets 1730.00M 1932.00M 1944.00M 1820.00M 1466.00M
Cash 1398.00M 1511.00M 1110.00M 541.00M 2171.00M
Total current liabilities 9513.00M 10432.00M 9231.00M 11842.00M 8517.00M
Current deferred revenue - 5555.00M 4503.00M 4692.00M 1347.00M
Net debt 9000.00M 9255.00M 10929.00M 12578.00M 6634.00M
Short term debt 1198.00M 2496.00M 2294.00M 4532.00M 2198.00M
Short long term debt 1073.00M 2379.00M 2182.00M 4423.00M 2196.00M
Short long term debt total 10398.00M 10766.00M 12039.00M 13119.00M 8805.00M
Other stockholder equity 6899.00M 5639.00M 4003.00M 5793.00M 16635.00M
Property plant equipment 8203.00M 7217.00M 6421.00M 6192.00M 4811.00M
Total current assets 12201.00M 10982.00M 9280.00M 9003.00M 9236.00M
Long term investments - - - 1612.08M 1691.55M
Net tangible assets 210.00M -3278.00M -6666.00M -8494.00M -3801.00M
Short term investments 244.00M 112.00M 29.00M 29.00M 8.00M
Net receivables 5776.00M 5365.00M 4771.00M 4994.00M 4194.00M
Long term debt 8834.00M 7928.00M 9418.00M 8129.00M 6605.00M
Inventory 4632.00M 3900.00M 3294.00M 3342.00M 2764.00M
Accounts payable 1595.00M 1542.00M 1768.00M 2054.00M 1144.00M
Total permanent equity - - - 0.00M 0.00M
Noncontrolling interest in consolidated entity - - - 0.00M 0.00M
Temporary equity redeemable noncontrolling interests - - - 0.00M 0.00M
Accumulated other comprehensive income - - - 0.00M 0.00M
Additional paid in capital - - - 0.00M 0.00M
Common stock total equity - - - 0.00M 0.00M
Preferred stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - 0.00M 0.00M
Treasury stock - - - 0.00M 0.00M
Accumulated amortization - - - 0.00M 0.00M
Non currrent assets other 432.00M 271.00M 151.00M 171.00M 169.00M
Deferred long term asset charges - - - 0.00M 0.00M
Non current assets total 36325.00M 34380.00M 32516.00M 34808.00M 27652.00M
Capital lease obligations 491.00M 459.00M 439.00M 567.00M 4.00M
Long term debt total - - - 0.00M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2743.00M -200.00M 62.00M -56.00M -20.00M
Change to liabilities 101.00M 433.00M 7.00M 201.00M 104.00M
Total cashflows from investing activities -2743.00M -1578.00M -1340.00M -6153.00M 2191.00M
Net borrowings -588.00M -1747.00M -835.00M 2591.00M -2056.00M
Total cash from financing activities -1555.00M -2504.00M -1522.00M 1902.00M -2825.00M
Change to operating activities -166.00M 75.00M -233.00M -238.00M -89.00M
Net income 3339.00M 3065.00M 1994.00M 1324.00M 3396.00M
Change in cash -45.00M 544.00M 574.00M -1389.00M 1581.00M
Begin period cash flow 1899.00M 1355.00M 781.00M 2170.00M 589.00M
End period cash flow 1854.00M 1899.00M 1355.00M 781.00M 2170.00M
Total cash from operating activities 4259.00M 4616.00M 3477.00M 2856.00M 2219.00M
Depreciation 2030.00M 1762.00M 1938.00M 1944.00M 1812.00M
Other cashflows from investing activities -1.00M -0.30M 2.00M -130.00M -130.00M
Dividends paid -239.00M -181.00M -168.00M -162.00M 755.00M
Change to inventory -604.00M -472.00M -85.00M -324.00M -172.00M
Change to account receivables -413.00M -310.00M -84.00M -47.00M -109.00M
Sale purchase of stock - - - 0.00M 0.00M
Other cashflows from financing activities 3185.00M 283.00M 5918.00M 4554.00M 393.00M
Change to netincome 217.00M 128.00M 130.00M 42.00M -2643.00M
Capital expenditures 1806.00M 1421.00M 1563.00M 1021.00M 1016.00M
Change receivables - - - 0.00M 0.00M
Cash flows other operating - - - 0.00M 0.00M
Exchange rate changes - - - 0.00M 0.00M
Cash and cash equivalents changes - - - 0.00M 0.00M
Change in working capital -1082.00M -274.00M -395.00M -408.00M -266.00M
Other non cash items -28.00M 63.00M -60.00M -4.00M -2723.00M
Free cash flow 2453.00M 3195.00M 1914.00M 1835.00M 1203.00M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MKKGY
Merck KGaA ADR		 0.85
2.56%		 34.06 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 2.55
1.52%		 170.00 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.31
1.49%		 21.06 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 40.91 - 10.66 0.01 1.16 2.94 23.11
TEVA
Teva Pharma Industries Ltd ADR		 -0.06
0.14%		 41.85 65.42 12.55 2.64 5.82 3.35 18.43

Profile*

Merck KGaA ADR

Merck KGaA operates as a science and technology company in Germany. The company's Life Science segment offers a range of products, including reagents, consumable, devices, instruments, software, and services for scientific discovery, as well as provides lab water instruments, consumables and services, microbiology and biomonitoring, products, test assays, analytical reagents, and flow cytometry kits and instruments for pharma and biotech, industrial and testing, academics and government, and diagnostic sectors. Its Healthcare segment designs and develops medicines and intelligent devices for treatment of various therapeutics, such as oncology, neurology and immunology, endocrinology, and general medicines. The company's Electronic segment provides semiconductor solutions, such as semiconductor materials, delivery systems and services, and intermolecular services for semiconductor and polymer removal chemistries applications; and display solutions comprising liquid crystals, OLED and quantum materials, reactive mesogens, photoresist materials, smart antenna, and dynamic liquid crystal glazing products, as well as offers liviFlex, a flexible platform, which offers a range of display materials. This segment also provides surface solution, such as cosmetics, effect pigments, and functional solutions; architecture solutions, including switchable windows; and automotive solutions. In addition, it has strategic alliances with Pfizer Inc. and GlaxoSmihKline plc to develop and commercialize active ingredients in immune-oncology; in-licensing agreement with Debiopharm International SA for developing drug candidates for the treatment of head and neck cancer; and out-licensing agreement with MoonLake Immunotherapeutics AG for developing a drug candidate for the treatment of inflammatory diseases. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Frankfurter Strasse 250, Darmstadt, Germany, 64293

49 6151 72 0

https://www.merckgroup.com

63297

Name Title Year Born
Ms. Belen Garijo Lopez M.D. Chair of Exec. Board & CEO 1960
Dr. Marcus Kuhnert CFO & Member of Exec. Board 1968
Dr. Kai Beckmann CEO of Electronics & Member of the Exec. Board 1965
Mr. Peter Guenter CEO of Healthcare Bus. & Member of Exec. Board 1962
Dr. Matthias J. Heinzel CEO of Life Science Sector & Member of Exec. Board 1967
Mr. Gerhard Schmitz Head of Global Accounting 1963
Mr. Dirk Toepfer Chief Information Officer NA
Mr. Constantin Fest Head of Investor Relations 1977
Dr. Friederike Rotsch Group Gen. Counsel and Head of Group Legal & Compliance 1972
Ms. Barbara Weiland Chief Compliance Officer 1974

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…